About Bio-Rad Laboratories (NYSE:BIO)
Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.
Industry, Sector and Symbol
Industry Medical Equipment, Supplies & Distribution
Sub-IndustryLife Sciences Tools & Services
Trailing P/E Ratio80.02
Forward P/E Ratio94.01
Sales & Book Value
Annual Sales$2.07 billion
Price / Sales3.63
Cash Flow$3.87 per share
Price / Cash65.10
Book Value$87.46 per share
Price / Book2.88
Net Income$28.12 million
Return on Equity3.44%
Return on Assets2.34%
Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions
What is Bio-Rad Laboratories' stock symbol?
Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."
How will Bio-Rad Laboratories' stock buyback program work?
Bio-Rad Laboratories announced that its board has authorized a share buyback plan on Wednesday, November 29th 2017, which permits the company to buyback $250,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.
How were Bio-Rad Laboratories' earnings last quarter?
Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its quarterly earnings data on Thursday, November, 2nd. The medical research company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.54 by $0.37. The medical research company earned $535 million during the quarter, compared to analyst estimates of $507.99 million. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. The company's revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.62 EPS. View Bio-Rad Laboratories' Earnings History.
When will Bio-Rad Laboratories make its next earnings announcement?
Where is Bio-Rad Laboratories' stock going? Where will Bio-Rad Laboratories' stock price be in 2017?
3 analysts have issued 12 month target prices for Bio-Rad Laboratories' shares. Their forecasts range from $255.00 to $290.00. On average, they anticipate Bio-Rad Laboratories' stock price to reach $273.33 in the next year. View Analyst Ratings for Bio-Rad Laboratories.
What are Wall Street analysts saying about Bio-Rad Laboratories stock?
Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:
- 1. According to Zacks Investment Research, "Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. " (12/13/2017)
- 2. Jefferies Group LLC analysts commented, "Time to forget everything you thought you knew about BIO -- as two separate updates y'day included several "firsts" that add conviction to our bullish thesis: 1) 2020 rev & margin goals; 2) capital allocation plan opens the door for buybacks; 3) board shuffle / quality upgrade. Bottom line: the pathway to $300+ in 2-3 yrs just got a lot clearer & BIO's new shareholder-friendly behavior eliminates the rationale for a structural valuation discount, in our view." (3/14/2017)
Who are some of Bio-Rad Laboratories' key competitors?
Some companies that are related to Bio-Rad Laboratories include CareFusion (CFN), Steris (STE), West Pharmaceutical Services (WST), Hill-Rom (HRC), DexCom (DXCM), ICU Medical (ICUI), VWR (VWR), Integra LifeSciences (IART), LivaNova (LIVN), Globus Medical (GMED), Neogen (NEOG), NuVasive (NUVA), Haemonetics (HAE), Inogen (INGN), Halyard Health (HYH), Nevro (NVRO), CONMED (CNMD) and MiMedx Group (MDXG).
Who are Bio-Rad Laboratories' key executives?
Bio-Rad Laboratories' management team includes the folowing people:
- Norman D. Schwartz, Chairman of the Board, President, Chief Executive Officer (Age 71)
- Christine A. Tsingos, Chief Financial Officer, Executive Vice President (Age 58)
- John P. Goetz, Chief Operating Officer, Executive Vice President (Age 67)
- Timothy Scott Ernst, Executive Vice President, General Counsel and Secretary (Age 57)
- Michael Crowley, Executive Vice President, Global Commercial Operations (Age 55)
- Shannon Hall, Executive Vice President, President, Life Science Group (Age 47)
- John Hertia, Executive Vice President, President, Clinical Diagnostics Group (Age 61)
- Giovanni Magni, Executive Vice President, Chief Strategy Officer (Age 60)
- Ronald W. Hutton, Vice President, Treasurer (Age 59)
- Alice N. Schwartz, Director (Age 90)
Who owns Bio-Rad Laboratories stock?
Bio-Rad Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Atlanta Capital Management Co. L L C (5.32%), TimesSquare Capital Management LLC (2.24%), American Century Companies Inc. (1.91%), Wells Fargo & Company MN (1.81%), NWQ Investment Management Company LLC (0.97%) and Cramer Rosenthal Mcglynn LLC (0.95%). Company insiders that own Bio-Rad Laboratories stock include Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Institutional Ownership Trends for Bio-Rad Laboratories.
Who sold Bio-Rad Laboratories stock? Who is selling Bio-Rad Laboratories stock?
Bio-Rad Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Atlanta Capital Management Co. L L C, Cramer Rosenthal Mcglynn LLC, NWQ Investment Management Company LLC, Intrepid Capital Management Inc., Investment Counselors of Maryland LLC, Russell Investments Group Ltd., SG Americas Securities LLC and Tygh Capital Management Inc.. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Insider Buying and Selling for Bio-Rad Laboratories.
Who bought Bio-Rad Laboratories stock? Who is buying Bio-Rad Laboratories stock?
Bio-Rad Laboratories' stock was bought by a variety of institutional investors in the last quarter, including American Century Companies Inc., Westfield Capital Management Co. LP, Claar Advisors LLC, TimesSquare Capital Management LLC, Asset Management One Co. Ltd., Citadel Advisors LLC, Epoch Investment Partners Inc. and Allianz Asset Management GmbH. View Insider Buying and Selling for Bio-Rad Laboratories.
How do I buy Bio-Rad Laboratories stock?
Shares of Bio-Rad Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bio-Rad Laboratories' stock price today?
One share of Bio-Rad Laboratories stock can currently be purchased for approximately $251.94.
How big of a company is Bio-Rad Laboratories?
Bio-Rad Laboratories has a market capitalization of $7.50 billion and generates $2.07 billion in revenue each year. The medical research company earns $28.12 million in net income (profit) each year or $0.79 on an earnings per share basis. Bio-Rad Laboratories employs 8,250 workers across the globe.
How can I contact Bio-Rad Laboratories?
Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]
MarketBeat Community Rating for Bio-Rad Laboratories (BIO)
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
|Community Ranking: || ||2.7 out of 5 ( )|
|Outperform Votes: || ||170 (Thanks for Voting!)|
|Underperform Votes: || ||148 (Thanks for Voting!)|
|Total Votes: || ||318|
Bio-Rad Laboratories (NYSE:BIO) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||2.67|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$250.00||$240.00||$240.00||$208.33|
|Price Target Upside: ||5.05% downside||4.53% upside||4.53% upside||3.06% downside|
Bio-Rad Laboratories (NYSE:BIO) Consensus Price Target History
Bio-Rad Laboratories (NYSE:BIO) Analyst Ratings History
(Data available from 12/18/2015 forward)
Bio-Rad Laboratories (NYSE:BIO) Earnings History and Estimates Chart
Bio-Rad Laboratories (NYSE BIO) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017||Q3 2017||$0.54||$0.91||$507.99 million||$535.00 million||View||N/A|
|5/4/2017||Q1 2017||$0.27||$0.41||$477.76 million||$500.05 million||View||Listen|
|2/23/2017||Q416||$1.03||($0.70)||$574.40 million||$571.45 million||View||N/A|
|11/1/2016||Q316||$0.51||$0.62||$480.60 million||$508.75 million||View||N/A|
|8/3/2016||Q2||$1.13||$0.61||$497.80 million||$516.80 million||View||N/A|
|5/5/2016||Q1||$0.60||$0.42||$463.90 million||$471.20 million||View||N/A|
|2/25/2016||Q415||$1.27||$1.68||$570.80 million||$570.56 million||View||Listen|
|11/3/2015||Q315||$0.54||$0.59||$495.55 million||$469.96 million||View||N/A|
|8/6/2015||Q215||$0.78||$0.97||$494.85 million||$506.10 million||View||N/A|
|5/5/2015||Q115||$0.33||$0.61||$474.60 million||$472.80 million||View||N/A|
|2/26/2015||Q414||$1.18||$1.34||$593.41 million||$598.20 million||View||N/A|
|11/4/2014||Q314||$0.86||$0.39||$525.40 million||$530.64 million||View||N/A|
|8/5/2014||Q214||$0.95||$1.09||$537.58 million||$536.80 million||View||N/A|
|5/6/2014||Q114||$0.80||$0.23||$515.00 million||$509.30 million||View||N/A|
|2/27/2014||Q413||$1.42||$1.04||$586.67 million||$602.60 million||View||Listen|
|11/7/2013||Q313||$0.91||($0.25)||$529.02 million||$505.10 million||View||Listen|
|8/6/2013||Q2 2013||$1.25||$1.20||$532.60 million||$525.30 million||View||Listen|
|5/7/2013||Q1 2013||$1.03||$0.68||$506.34 million||$499.70 million||View||N/A|
|2/26/2013||Q4 2012||$1.33||$1.65||$558.68 million||$573.80 million||View||N/A|
|11/6/2012||Q312||$1.14||$1.48||$507.79 million||$498.70 million||View||N/A|
Bio-Rad Laboratories (NYSE:BIO) Earnings Estimates
2017 EPS Consensus Estimate: $3.22
2018 EPS Consensus Estimate: $4.76
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Bio-Rad Laboratories (NYSE:BIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Bio-Rad Laboratories (NYSE BIO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.29%
Institutional Ownership Percentage: 63.91%
Bio-Rad Laboratories (NYSE BIO) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/14/2017||Christine A Tsingos||CFO||Sell||4,980||$249.40||$1,242,012.00|| |
|12/4/2017||Michael Crowley||EVP||Sell||1,000||$258.39||$258,390.00|| |
|11/30/2017||James R. Stark||VP||Sell||746||$270.51||$201,800.46|| |
|11/14/2017||Giovanni Magni||EVP||Sell||2,400||$253.01||$607,224.00|| |
|8/11/2017||Michael Crowley||EVP||Sell||700||$215.91||$151,137.00|| |
|3/7/2017||Michael Crowley||EVP||Sell||300||$196.13||$58,839.00|| |
|11/9/2016||James R. Stark||VP||Sell||1,299||$171.42||$222,674.58|| |
Bio-Rad Laboratories (NYSE BIO) News Headlines
|GW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in Session|
finance.yahoo.com - December 15 at 11:51 AM
|Bio-Rad Laboratories, Inc. (BIO) CFO Christine A. Tsingos Sells 4,980 Shares|
www.americanbankingnews.com - December 14 at 8:52 PM
|Protein Expression Market, 2023|
finance.yahoo.com - December 14 at 3:44 PM
|Bio-Rad Laboratories (BIO) Rating Increased to Strong-Buy at Zacks Investment Research|
www.americanbankingnews.com - December 13 at 4:46 PM
|Global Protein Expression Market 2016-2023: Market is Expected to Grow from $1.4 Billion to $3.0 Billion|
www.benzinga.com - December 13 at 3:44 PM
|Zacks: Brokerages Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Post Quarterly Sales of $617.23 Million|
www.americanbankingnews.com - December 12 at 1:56 AM
| Analysts Expect Bio-Rad Laboratories, Inc. (BIO) Will Announce Earnings of $1.27 Per Share|
www.americanbankingnews.com - December 10 at 11:32 PM
|Bio-Rad Laboratories, Inc. (BIO) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - December 10 at 1:52 AM
|ETFs with exposure to Bio-Rad Laboratories, Inc. : December 7, 2017|
finance.yahoo.com - December 7 at 3:47 PM
|Outstanding Measures for Earnings Momentum Keep Bio Rad Laboratories (BIO) a Strong Buy|
investorplace.com - December 7 at 12:23 PM
|Bio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017|
finance.yahoo.com - December 5 at 1:00 PM
|Michael Crowley Sells 1,000 Shares of Bio-Rad Laboratories, Inc. (BIO) Stock|
www.americanbankingnews.com - December 4 at 9:02 PM
|Bio-Rad (BIO) at a 52-Week High: What's Driving the Stock?|
www.zacks.com - December 1 at 6:30 PM
|Bio-Rad Laboratories, Inc. (BIO) VP James R. Stark Sells 746 Shares|
www.americanbankingnews.com - November 30 at 8:22 PM
|Best-in-Class Metrics for Earnings Growth Keep Bio Rad Laboratories (BIO) a Strong Buy|
investorplace.com - November 30 at 12:04 PM
|Bio-Rad Laboratories (BIO) Earns "Outperform" Rating from Wells Fargo & Company|
www.americanbankingnews.com - November 29 at 7:30 PM
|Bio-Rad Laboratories (BIO) to Repurchase $250.00 million in Outstanding Stock |
www.americanbankingnews.com - November 29 at 11:10 AM
|BRIEF-Bio-Rad Authorizes New $250 Million Share Repurchase Program|
www.reuters.com - November 28 at 3:39 PM
|Bio-Rad Labs (BIO) Announces $250M Stock Buyback|
www.streetinsider.com - November 28 at 3:39 PM
|Bio-Rad Authorizes New $250 Million Share Repurchase Program|
finance.yahoo.com - November 28 at 3:39 PM
|Comparing Bio-Rad Laboratories (BIO) & ICU Medical (ICUI)|
www.americanbankingnews.com - November 26 at 9:40 AM
|Bio Rad Laboratories (BIO) a Strong Buy on High-Level Quant Score|
investorplace.com - November 23 at 12:21 PM
|$1.27 EPS Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter|
www.americanbankingnews.com - November 23 at 1:26 AM
|Global Immunoassay Reagents and Devices Market Expected To Be Worth US$ 26.00 Billion By 2022|
www.marketwatch.com - November 22 at 10:12 PM
|Bio-Rad to Webcast Investor Day 2017|
finance.yahoo.com - November 21 at 11:21 PM
|Global high throughput screening market analysis and forecast to 2022 made available by Meticulous Research™|
globenewswire.com - November 21 at 3:29 PM
|Single Cell Analysis Market to Grow Owing to Rising Prevalence of Life Threatening Diseases Till 2024 | Million Insights|
www.marketwatch.com - November 21 at 3:54 AM
|Bio-Rad Laboratories, Inc. (BIO) Upgraded to B- by TheStreet|
www.americanbankingnews.com - November 19 at 8:16 PM
|ETFs with exposure to Bio-Rad Laboratories, Inc. : November 17, 2017|
finance.yahoo.com - November 17 at 4:10 PM
|Bio-Rad Laboratories, Inc. (BIO) EVP Sells $607,224.00 in Stock|
www.americanbankingnews.com - November 15 at 8:20 PM
|Bio-Rad Laboratories, Inc. (BIO) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - November 15 at 1:46 AM
|Rating on Bio Rad Laboratories (BIO) Raised to Strong Buy From a Buy|
investorplace.com - November 9 at 1:49 PM
|BIO Crosses Above Average Analyst Target|
www.nasdaq.com - November 7 at 7:18 PM
|Bio-Rad Laboratories, Inc. (BIO) Upgraded by Zacks Investment Research to Hold|
www.americanbankingnews.com - November 7 at 5:18 PM
|Bio-Rad posts 3Q profit|
finance.yahoo.com - November 6 at 5:35 PM
|$628.03 Million in Sales Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter|
www.americanbankingnews.com - November 5 at 6:22 AM
|Bio-Rad Laboratories, Inc. (BIO) Expected to Post Earnings of $1.76 Per Share|
www.americanbankingnews.com - November 3 at 11:19 PM
|Bio-Rad Laboratories, Inc. (BIO) Issues Earnings Results|
www.americanbankingnews.com - November 3 at 5:02 PM
|Edited Transcript of BIO earnings conference call or presentation 2-Nov-17 9:00pm GMT|
finance.yahoo.com - November 3 at 8:38 AM
|Bio-Rad Laboratories (BIO) Q3 2017 Results - Earnings Call Transcript|
seekingalpha.com - November 2 at 10:11 PM
|Bio-Rad tops Street 3Q forecasts|
finance.yahoo.com - November 2 at 10:11 PM
|Bio-Rad Reports Third-Quarter 2017 Financial Results|
finance.yahoo.com - November 2 at 5:08 PM
|Quant Score Makes Bio Rad Laboratories (BIO) a Buy|
investorplace.com - November 2 at 12:54 PM
|New Strong Sell Stocks for November 1st|
finance.yahoo.com - November 1 at 5:11 PM
|Bio-Rad Laboratories, Inc. – Value Analysis (NYSE:BIO) : October 31, 2017|
finance.yahoo.com - October 31 at 5:41 PM
|Bio-Rad Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : BIO-US : October 30, 2017|
finance.yahoo.com - October 30 at 5:35 PM
|ETFs with exposure to Bio-Rad Laboratories, Inc. : October 27, 2017|
finance.yahoo.com - October 27 at 6:54 PM
|Bio Rad Laboratories (BIO) a Buy on Solid Quant Score|
investorplace.com - October 26 at 12:43 PM
|Bio-Rad Laboratories, Inc. (BIO) to Release Quarterly Earnings on Monday|
www.americanbankingnews.com - October 23 at 10:54 AM
|Bio Rad Laboratories (BIO) a Buy on Strong Quant Score|
investorplace.com - October 19 at 12:40 PM
Bio-Rad Laboratories (NYSE:BIO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bio-Rad Laboratories (NYSE:BIO) Income Statement, Balance Sheet and Cash Flow Statement
Bio-Rad Laboratories (NYSE BIO) Stock Chart for Monday, December, 18, 2017